ACTRN12618000850279招募中4 期
How to choosebetweenamab for severe asthma, Mepolizumab is as effective as Omalizumab in improving asthma symptom control, as measured by the asthma control questionnaire (ACQ5), for patients with severe allergic and eosinophilic asthma.
Peter Wark0 个研究点目标入组 200 人开始时间: 2018年5月21日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 12 Years 至 85 Years（—）
- 性别
- All
入选标准
- •Participants must have a duration of asthma of greater than one year.
- •They must have confirmed asthma defined as: (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12%, and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days.
- •They must have evidence of poor asthma control despite optimal ICS and long acting beta agonist (LABA), be treated by a respiratory physician or immunologist, and have demonstrated acceptable adherence and inhaler technique. Poor control is defined as: evidence of an FEV1 <80% of predicted in the last year on at least one occasion; treatment with OCS, either daily for at least 6 weeks, or a cumulative dose of OCS of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated. In addition they must demonstrate an: (a) an Asthma Control Questionnaire (ACQ-5)38 score of at least 2.0, as assessed in the previous month, and (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, or 1 severe asthma exacerbation, requiring documented use of OCS initiated or increased for at least 3 days, or parenteral corticosteroids prescribed/supervised by a physician.
- •They must also demonstrate evidence of a dual allergic/ eosinophilic phenotype. This is defined as: a total serum IgE >30IU/mL, past or current evidence of atopy documented by skin prick testing or radioallergosorbent assay, and the participant must have a blood eosinophil count greater than or equal to 300 cells per microlitre in the last 6 weeks.
排除标准
- •Do not fulfil inclusion criteria
- •Unable to attend appointments
- •Significant psychiatric illness
- •Unable to speak English
研究者
相似试验
Unknown
4 期
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".AsthmaEosinophilic AsthmaNCT04585997University of Newcastle, Australia200
撤回
不适用
Omalizumab for Asthma with Non-detectable Sensitization to an Aeroallerge10006436AsthmaNL-OMON42417eids Universitair Medisch Centrum60
暂停
不适用
Australian Mepolizumab Registry (AMR) for Severe AsthmaACTRN12618001497291Hunter New England Local Health District400
Unknown
不适用
Mepolizumab Effectiveness in Severe Eosinophilic Asthma and BronchiectasisBronchial AsthmaBronchiectasisNCT05189613Policlinico Universitario, Catania100
已完成
不适用
Mepolizumab Pharmacokinetics Among Patients With Severe AsthmaAsthmaNCT05495932University Hospital, Montpellier50